SensoDetect: Patent granted in Australia

Patent- System and method for improved determination of a brain response state in Australia has now been granted and Sensodetect have achieved the registreings and approval papers via the patent attorney AWA patent. The patent is valid until 2037.

Granting of this patent strengthens our patent portfolio in Australia (AU 2013229590 B2) which is an interesting and in many ways modern market.

Patent abstract summary "A device and a method for detecting a brain response state of a subject id disclosed. The detection comprises repeatedly presenting the subject with a sound stimulus for evoking a brain response. Detecting the evoked brain response signal related to each of said sound stimulus."

In all countries, similar problems exist in psychiatry, which in Sweden and Australia is no exception. According to the WHO, about 25% of the world's population suffer from mental illness. The queues for psychiatry grow rapidly in all parts of the world. Therefore, the need for new tools is particularly highlighted in many markets. Interest is in psychiatry where SensoDetect BERA can be used for screening or as a decision support. Also, as a tool in research, SensoDetect BERA is useful, for example, the tool can be used to study different drug effects, etc. The currently granted patents significantly enhance SensoDetect's protection in Australia, where there are several actors and researchers who may be future competitors or stakeholders regarding SensoDetects platform BERA and the associated analysis tools. It is therefore an important step in our protection of Sensodetect.

"SensoDetect significantly strengthens its IP portfolio in an interesting and modern market. Then psychiatry wrestles there with the same challenges as psychiatry in Sweden with growing queues and the number of incidence. I am especially pleased when I note that the new patents concern markets where we can very well meet new competitors and stakeholders who see business opportunities in the area that SensoDetect operates. This is and can become a very interesting market, although it is not in the imediate plan, it may well emerge as a new opportunity. Our IP portfolio is now very strong, although it is, not always reflected in the valuation of the company today.", says CEO, Johan Olson at Sensodetect.

Johan Olson

VD, SensoDetect Aktiebolag (publ)

Phone: +46 705 424600



Jan Andersson

Chairman of the board, SensoDetect Aktiebolag (publ)

Phone: +46 793 472280


This information is information that SensoDetect AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on Oktober 13th 2017.

SensoDetect highlights through patented equipment brain stem responses to audio stimuli in order to provide health care clear anomalies and patterns for use primarily within psychiatry. The goal is to increase efficiency in Psychiatry and thus the benefits for health care, society, patients and relatives.

Our Mission
Improve the lives of people with mental illness
Our Vision
Making ABR profiling tests with SensoDetect technology an integral part of setting diagnosis for mental illness
Our Value Proposition:
SensoDetect provides a complete audiogram for the brainstem, helping health care professional to set psychiatric diagnoses objectively and
cost effectively. This unique offering improves patients’ quality of life and reduces the economic impact on the health care system and society

  Further information about SensoDetect

Publicerat: 10/13/2017 11:54:06 AM

Nyheten distribueras av AktieTorget i samarbete med Cision.
För att prenumerera på nyheter på detta bolag, klicka här.

  • Mäster Samuelsgatan 42
  • 111 57 Stockholm
  • Telefon: 08 - 511 68 000
  • info(snabel-a)aktietorget(punkt)se